Why the study?
Do cholinesterase inhibitors decrease long-term cognitive decline and risk of death in patients with Alzheimer dementia?
Do cholinesterase inhibitors decrease long-term cognitive decline and risk of death in patients with Alzheimer dementia?
Cholinesterase inhibitors, particularly galantamine, are associated with decreased long-term cognitive decline, risk of severe dementia, and mortality in patients with Alzheimer dementia.
This study provides Class III evidence that for patients with Alzheimer dementia ChEIs decrease long-term cognitive decline and risk of death and that galantamine decreases the risk of severe dementia.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: